Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02808650 · ClinicalTrials.gov registry record · Phase 1
Prexasertib in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors
A Phase 1 study, sponsored by Children's Oncology Group.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT02808650 is a Phase 1 study that has completed, run by Children's Oncology Group. The registered enrollment target is 30 participants.
The verdict
NCT02808650, a Phase 1 study, has completed, sponsored by Children's Oncology Group.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
This phase I trial studies the side effects and best dose of prexasertib in treating pediatric patients with solid tumors that have come back after a period of time during which the tumor could not be detected or does not respond to treatment. Checkpoint kinase 1 inhibitor LY2606368 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Interventions
- OTHER Laboratory Biomarker Analysis
- DRUG Prexasertib
- OTHER Pharmacokinetic (PK) study
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2017-02-27 |
| Est. Completion | 2021-03-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02808650
The ClinicalTrials.gov registry entry for NCT02808650 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Children's Oncology Group, which has 342 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT02808650 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02808650 about?
NCT02808650 is a clinical study titled "Prexasertib in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors". This phase I trial studies the side effects and best dose of prexasertib in treating pediatric patients with solid tumors that have come back after a period of time during which the tumor could not be detected or does not respond to treatment. Checkpoint kinase 1 inhibitor LY2606368 may stop the gro...
What is the current status of trial NCT02808650?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2017-02-27. Estimated completion is 2021-03-31.
What interventions are being tested in trial NCT02808650?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Prexasertib (DRUG), Pharmacokinetic (PK) study (OTHER).
Who is sponsoring clinical trial NCT02808650?
This trial is sponsored by Children's Oncology Group, which has 342 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.